The game attempts to assess whether someone has Alzheimer's by evaluating how well they respond to distractions and interruptions.
Contract researcher Avillion launched last year with a novel approach to contract drug development, planning to team up with Big Pharmas on late-stage assets and take drugs to the finish line in exchange for a cut of the proceeds. Now the London company has reeled in a big-name partner in Pfizer, signing on to run a Phase III study of the cancer-fighting Bosulif.
When it comes to Alzheimer's research, success stories are few and far between. Therapeutic programs center around vaccines and drugs, but Akili Interactive Labs wants to change all that: The Boston-based startup recently signed a deal with Pfizer to see if its mobile video game platform can help diagnose early signs of Alzheimer's.
Impax Laboratories is tapping Durect Corporation for its mid-stage transdermal patch Eladur, which is designed to ease the pain associated with shingles. For exclusive rights to the delivery tech, Impax agreed to pay up to $63 million to Durect when all is said and done.
Fever is a common side effect of many vaccinations; an estimated one-third of people receiving Pfizer's Prevnar 13 develop a mild case. Flu vaccines also cause cases, prompting researchers to investigate a question--does giving the shots simultaneously raise the risk of fever? The resulting study suggests the answer is yes.
Foreign drugmakers have had their fair share of struggles in China this year as the country looked to cut down on healthcare spending and root out bribery. But neither of those factors caused a Tuesday holdup of a Pfizer drug. Instead, the company is blaming a paperwork problem for an import suspension on antifungal drug Diflucan.
When Pfizer unveiled plans to carve up the business into three units, the company's top lawyer Amy Schulman was one of the big winners. Schulman was to take charge of a new unit that combined the vaccine, cancer and consumer products businesses. Now, two weeks before Schulman was due to start in the role, she is out of a job.
After years of wrangling over Pfizer's patent on Viagra, Teva Pharmaceutical Industries has made a deal. Under an agreement with Pfizer, the Israeli generics giant can launch its version of the blockbuster pill on Dec. 11, 2017, more than two years before its final patent protection expires.
As recently as last Thursday, Pfizer's Amy Schulman was fully expecting to move into a new and better job at Pfizer on Jan. 1. By Tuesday, she was out of a job altogether. So writes Fortune' s Patricia Sellers, who lunched with Schulman last week in New York.
In July, Amy Schulman looked to be one of the most powerful women in Big Pharma. As part of CEO Ian Read's plan to split Pfizer's internal operations into three distinct units, he tapped Schulman to lead the company's vaccines, oncology and consumer healthcare business. Now, Schulman is out.